Compare PubMatic Inc (PUBM) vs Summit Therapeutics Inc (SMMT) Price & Performance

PUBM trades at $16.29, down 1.27% on the day, with a bullish technical signal supported by moving averages and recent crossing above the 20-day average. The company reported Q2 2026 revenue growth of 10.5% year-over-year and an EPS beat, driven by mobile app and CTV segments. Analyst consensus is strongly positive with 11 buy ratings and a $20.83 price target, implying 28% upside from current levels.

The outlook is cautiously optimistic given strong revenue momentum and AI product adoption, but negative net margins and high P/E of 132 pose valuation risks. Key catalysts include continued execution in high-margin segments and leadership transitions, while competitive pressures and macroeconomic headwinds remain concerns for sustained profitability.

Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.

The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.